- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01483170
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Primary Objectives: To assess safety and tolerability of two different fexinidazole dosing regimen, for 10 days repeated administration under fed conditions in healthy male sub-Saharan volunteers.
Secondary objectives: To validate the exposure to fexinidazole, M1 and M2 after different dosing regimens in fed conditions for 10 days in order to evaluate the more appropriate administration regimen for the pivotal phase II/III study.
Methodology/Study Design:
Two dose regimens consisting of repeated oral ascending dose (OAD) dosing in fed condition with two different ascending loading doses for 4 days followed by the same dose for 6 days will be evaluated. The study will be conducted in double-blind conditions for both the clinical and bioanalytical parts.
For each dosing regimen, subjects will reside at the clinical unit from the evening of Day -2 to the afternoon of Day 17 including an 8 days safety follow up (168 h post last dose).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- SGS Life Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male healthy volunteers 18 to 45 years of age,
- All subjects to be of sub-Saharan African origins with both parents of sub-Saharan African origins too,
- Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2 from 18 to 28 kg/m2 inclusive at screening,
- Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study,
- Provision of written informed consent to participate as shown by a signature on the volunteer consent form,
- Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study,
- Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min,
- Registered with the French Social Security in agreement with the French law on biomedical experimentation.
Exclusion Criteria:
- Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection,
- With any clinically significant abnormality following review of pre-study laboratory tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital signs, full physical examination and ECG,
- Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health,
- Who forfeit their freedom by administrative or legal award or who were under guardianship,
- Unwilling to give their informed consent,
- Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti-HCV antibodies
- Who have a history of allergy, intolerance or photosensitivity to any drug,
- Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,
- Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol),
- Who drink more than 8 cups daily of beverage containing caffeine,
- Who have a positive laboratory test for urine drug screening (opiates, cocaine,amphetamine, cannabis, benzodiazepines),
- Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,
- Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration,
- Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study,
- Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fexinidazole
|
Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
|
Placebo Comparator: Placebo fexinidazole
|
Placebo fexinidazole
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lionel Hovsepian, MD, SGS Aster
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DNDiFEX003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trypanosomiasis, African
-
Drugs for Neglected DiseasesInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsNot yet recruitingHuman African Trypanosomiasis
-
Drugs for Neglected DiseasesSanofiCompletedHuman African TrypanosomiasisFrance
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedTrypanosoma Brucei Gambiense; Infection | Sleeping Sickness; West African | African Trypanosomiases | West African; TrypanosomiasisCongo, The Democratic Republic of the, Côte D'Ivoire, Guinea
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | African Trypanosomiases | West African Sleeping Sickness | Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, GambienseCongo, The Democratic Republic of the, Côte D'Ivoire, Burkina Faso
-
Institute of Tropical Medicine, BelgiumCompletedHuman African TrypanosomiasisCongo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedSleeping Sickness | Human African Trypanosomiasis (HAT)Central African Republic, Congo, The Democratic Republic of the, Congo
-
Drugs for Neglected DiseasesSwiss Tropical & Public Health Institute; Ministry of Public Health, Democratic...Completed
-
Institut de Recherche pour le DeveloppementFoundation for Innovative New Diagnostics; Programme National de lutte contre... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | West African Sleeping SicknessCôte D'Ivoire, Guinea
Clinical Trials on Tablets Fexinidazole
-
SanofiCompletedHepatic Function AbnormalBulgaria, France
-
Drugs for Neglected DiseasesSanofiCompletedPK in Healthy VolunteersFrance
-
Drugs for Neglected DiseasesCompletedTrypanosomiasis, AfricanFrance
-
Drugs for Neglected DiseasesSanofiCompletedTrypanosomiasis, African | Sleeping Sickness | Trypanosomiasis; GambianCongo, The Democratic Republic of the, Guinea
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesSanofiCompletedHuman African TrypanosomiasisFrance
-
Drugs for Neglected DiseasesEuropean and Developing Countries Clinical Trials Partnership (EDCTP)CompletedTrypanosoma Brucei Rhodesiense; InfectionMalawi, Uganda
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesTerminatedVisceral LeishmaniasisSudan
-
Drugs for Neglected DiseasesCompletedChagas' Disease (Chronic) NosSpain